ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2684

Regional and Whole Gut Transit Times in Patients with Systemic Sclerosis Using the Wireless Motility Capsule

Neetu Bali1, Isela Valera2, Aly Aly3, Jeffrey Conklin4, Daniel E. Furst5 and Suzanne Kafaja6, 1Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 3Chamblion St,, Alexandria Faculty of Medicine, Alexandria, Egypt, 4Medicine, Division of Digestive Diseases at UCLA, Los Angeles, CA, Los Angeles, CA, 5David Geffen School of Medicine at UCLA, Los Angeles, CA, 6Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Gastrointestinal complications and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Gastrointestinal tract (GI) is one of the most commonly affected systems in systemic sclerosis (SSc), impacting the lives of up to 90% of patients, irrespective of their disease subtype. Of the GI manifestations in SSc, GI dysmotility impacts as many as 90% of patients with SSc. Various GI modalities are used to assess and aid in the diagnosis of GI tract motility compromise. The wireless motility capsule (WMC) is an ambulatory, noninvasive and ingestible device that measures intraluminal pressure, pH, and temperature changes as it moves through the GI tract. This helps evaluate regional and whole gut transit times, as well as phasic GI motor activity.

Objective: To describe the regional and whole gut transit times in patients with SSc and to evaluate relationship between GI transit time and other organ manifestation in SSc disease.

Methods: This was a retrospective analysis of all SSc patients from the UCLA SSc program and the UCLA- database, meeting the 2013 ACR/EULAR SSc classification criteria, ≥ 18 y.o, and having had a WMC test performed from July 1, 2013 to July 1, 2016. We reported both regional (gastric emptying, small bowel, and colonic transit times) as well as whole gut transit times. We evaluated other rheumatologic manifestations, including: interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), creatinine clearance (CrCl), and diffuse vs. limited disease. Additionally, we reported patient-reported symptoms related to upper and lower GI transit, including GERD, heartburn, regurgitation, vomiting, dysphagia, constipation, and diarrhea. Statistical analyses of numerical variables were assessed using Wilcoxon rank sum tests and T-tests and categorical variables were assessed using Fisher’s exact tests.

Results: A total of 35 patients met our inclusion criteria. The median age was 57.5 years. There were 34 (97%) women; 23 (65%) were white/Caucasian; 28 (80%) were non-Hispanic/Latino; 25 (71.4%) had limited SSc; 22 (62.9%) had ILD; 16 (45.7%) had PAH. The mean CrCl was 78.1 with SD of 24.8. No statistically significant correlation was noted between regional and/or whole gut motility and other SSc organ manifestation. We found that 42.9% had decreased gastric emptying; 37.5% had decreased small bowel transit time; 33.3% had decreased colonic transit time.

Conclusion: In this small cohort, we did not find a significant correlation between regional and whole gut transit times and other manifestations of SSc. Interestingly, we found a discrepancy between patient-reported symptoms and WMC transit times, indicating that symptomatology may not be correlated with a decrease in regional GI transit times. A larger cohort study is needed to verify our findings.


Disclosure: N. Bali, None; I. Valera, None; A. Aly, None; J. Conklin, None; D. E. Furst, Grant/Research Support: Amgen,BMS Novartis, Pfizer, Roche/Genentech,Corbus. Consultant:AbbVie, Amgen, BMS, Corbus, Cytori, , Novartis, Pfizer, Roche/Genentech,. Speakers Bureau(CME or non-promotional only): BMS, Abbvie NO stocks, royalties, direct fina, 2,see above, 5,see above, 8; S. Kafaja, None.

To cite this abstract in AMA style:

Bali N, Valera I, Aly A, Conklin J, Furst DE, Kafaja S. Regional and Whole Gut Transit Times in Patients with Systemic Sclerosis Using the Wireless Motility Capsule [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/regional-and-whole-gut-transit-times-in-patients-with-systemic-sclerosis-using-the-wireless-motility-capsule/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/regional-and-whole-gut-transit-times-in-patients-with-systemic-sclerosis-using-the-wireless-motility-capsule/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology